VEGFA and non-small cell lung carcinoma: In phase 1 and 2 studies of advanced non—small cell lung cancer (NSCLC), treatment with the VEGF inhibitor bevacizumab plus erlotinib resulted in response rates of 17.5% to 20.0% [9-11].